Irinotecan and Temozolomide for Ewing Sarcoma: The Memorial Sloan-Kettering Experience
Irinotecan and Temozolomide for Ewing Sarcoma: The Memorial Sloan-Kettering Experience
复制标题
DOI：
10.1002/pbc.22206
复制
发表时间：
2009-12-01
影响因子：
3.2
通讯作者：
Meyers, Paul A.
中科院分区：
文献类型：
--
作者：
Casey, Denise A.;Wexler, Leonard H.;Meyers, Paul A.
背景复发/进展性尤文肉瘤（ES）的预后仍然很差。临床前、成人I期和II期试验已证明伊立替康和替莫唑胺联合用药具有方案依赖性协同作用和显著的抗肿瘤活性。一项儿科I期试验表明，该方案在晚期ES中是安全和有效的。Procedure.我们进行了一项回顾性病历审查，以确定在我们机构接受伊立替康[20 mg/m2/d x 5 x 2]和替莫唑胺（100 mg/m2/d x 5）治疗的复发性/进展性ES患者。记录达到的最佳缓解、至进展时间（TTP）和相关毒性。结果20例患者共接受了154个周期的治疗。在19例可评价患者中，有5例完全缓解和7例部分缓解（总体客观缓解率为63%）。20例复发性/进展性ES可评价患者的中位TTP为8.3个月; 14例复发性ES患者的亚组为16.2个月。首次缓解持续2年的患者中位TTP优于复发患者
Background. The prognosis for recurrent/progressive Ewing sarcoma (ES) remains poor. Pre-clinical, adult phase I and II trials have demonstrated the combination of irinotecan and temozolomide to have schedule-dependent synergy and significant antitumor activity. A pediatric phase I trial has shown this regimen to be safe and active in advanced ES. Procedure. We conducted a retrospective chart review to identify patients with recurrent/progressive ES treated with irinotecan [20 mg/m(/)(2)day x 5(x 2)] and temozolomide (100 mg/m(2)/day x 5) in our institution. The best response achieved, time to progression (TTP), and associated toxicities were recorded. Results. Twenty patients received a total of 154 cycles of therapy. Of 19 evaluable patients, there were 5 complete and 7 partial responses (a 63% overall objective response). Median TTP for 20 evaluable patients with recurrent/progressive ES was 8.3 months; for the subset of 14 patients with recurrent ES, it was 16.2 months. Median TTP was better for patients who Sustained a 2-year first remission than for those who relapsed